The year 2017 may have been a historic one for the US FDA's Center for Drug Evaluation and Research (CDER) in terms of new drugs approved, but the composition of the novel product class remained relatively consistent compared with recent years.
CDER's 2017 New Drug Class Maintains Steady Innovative Composition With Recent Years
New drugs approved in 2017 were not significantly different than those from years past in terms of innovative characteristics, but accelerated approval percentage took a sharp drop.